Literature DB >> 33277419

Parkinson Disease Propagation Using MRI Biomarkers and Partial Least Squares Path Modeling.

Nadya Pyatigorskaya1, Lydia Yahia-Cherif2, Romain Valabregue2, Rahul Gaurav2, Fatma Gargouri2, Claire Ewenczyk2, Cecile Gallea2, Sara Fernandez-Vidal2, Isabelle Arnulf2, Marie Vidailhet2, Stephane Lehericy2.   

Abstract

OBJECTIVES: The classic Braak neuropathologic staging model in Parkinson disease (PD) suggests that brain lesions progress from the medulla oblongata to the cortex. An alternative model in which neurodegeneration first occurs in the cortex has also been proposed. These 2 models may correspond to different patient phenotypes. To test these 2 models and to investigate whether they were influenced by the presence of REM sleep behavior disorder (RBD), we used multimodal MRI and partial least squares path modeling (PLS-PM) assuming that patients with RBD followed distinct neurodegeneration pattern.
METHODS: Fifty-four patients with PD (34 with RBD) and 25 healthy volunteers were scanned with T1-weighted, diffusion tensor, and neuromelanin-sensitive imaging. Volume, signal, and mean, axial, and radial diffusivities were calculated in brainstem, basal forebrain, and cortical regions. PLS-PM, estimating a network of causal relationships between blocks of variables, was used to build and test an analytical model based on Braak staging. The overall quality of the model was assessed with goodness of fit coefficient (Gof).
RESULTS: PLS-PM was run on patients with PD with RBD and without RBD separately. In PD with RBD, a brainstem-to-cortex model had significant Gof (0.71, p = 0.01), whereas a cortex-to-brainstem model did not. In contrast, in patients with PD without RBD, the brainstem-to-cortex model was not significant (Gof = 0.64, p = 0.27), and the cortex-to-brainstem model was highly significant (Gof = 0.72, p = 0.008).
CONCLUSIONS: With the PLS-PM imaging-based model, the neurodegeneration pattern of patients with PD with RBD was consistent with the Braak brainstem-to-cortex model, whereas that of patients without RBD followed the cortex-to-brainstem model.
© 2020 American Academy of Neurology.

Entities:  

Year:  2020        PMID: 33277419     DOI: 10.1212/WNL.0000000000011155

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Disruption of Brainstem Structural Connectivity in REM Sleep Behavior Disorder Using 7 Tesla Magnetic Resonance Imaging.

Authors:  María G García-Gomar; Aleksandar Videnovic; Kavita Singh; Matthew Stauder; Laura D Lewis; Lawrence L Wald; Bruce R Rosen; Marta Bianciardi
Journal:  Mov Disord       Date:  2021-12-29       Impact factor: 9.698

2.  Brain atrophy progression in Parkinson's disease is shaped by connectivity and local vulnerability.

Authors:  Christina Tremblay; Shady Rahayel; Andrew Vo; Filip Morys; Golia Shafiei; Nooshin Abbasi; Ross D Markello; Ziv Gan-Or; Bratislav Misic; Alain Dagher
Journal:  Brain Commun       Date:  2021-11-17

3.  White matter microstructure in Parkinson's disease with and without elevated rapid eye movement sleep muscle tone.

Authors:  Rémi Patriat; Pramod K Pisharady; Sommer Amundsen-Huffmaster; Maria Linn-Evans; Michael Howell; Jae Woo Chung; Matthew N Petrucci; Aleksandar Videnovic; Erin Holker; Joshua De Kam; Paul Tuite; Christophe Lenglet; Noam Harel; Colum D MacKinnon
Journal:  Brain Commun       Date:  2022-02-09

4.  The Myelin-Weighted Connectome in Parkinson's Disease.

Authors:  Tommy Boshkovski; Julien Cohen-Adad; Bratislav Misic; Isabelle Arnulf; Jean-Christophe Corvol; Marie Vidailhet; Stéphane Lehéricy; Nikola Stikov; Matteo Mancini
Journal:  Mov Disord       Date:  2021-12-22       Impact factor: 9.698

Review 5.  Oligomeropathies, inflammation and prion protein binding.

Authors:  Gianluigi Forloni; Pietro La Vitola; Claudia Balducci
Journal:  Front Neurosci       Date:  2022-08-23       Impact factor: 5.152

6.  Dying-back of ascending noradrenergic projections in Parkinson's disease.

Authors:  Rick C Helmich; Stéphane Lehéricy
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.